OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

Benjamin Besse, Mark M. Awad, Patrick M. Forde, Michael Thomas, K. Park, Geraldine Goss, Naiyer A. Rizvi, Florian Huemer, Maximilian J. Hochmair, Jaafar Bennouna, Jan Cosaert, Zoltán Szűcs, Peter G. Mortimer, Rosalind Hobson, Kris F. Sachsenmeier, Emma Dean, Helen Ambrose, C. Hayward, M. Dressman, Simone Barry, John V. Heymach